Whitehawk Therapeutics (WHWK) EBT Margin (2018 - 2025)
Whitehawk Therapeutics (WHWK) reported EBT Margin of 1021.92% for Q1 2025, up 136356.0% year-over-year from N/an in Q1 2024, and up 504.84% quarter-over-quarter from 252.42% in Q4 2024.
Whitehawk Therapeutics (WHWK) EBT Margin (2018 - 2025) Analysis & Trends
Whitehawk Therapeutics (WHWK) has 7 years of EBT Margin data on file, last reported at 1021.92% in Q1 2025.
- EBT Margin for Q1 2025 came in at 1021.92%, up 136356.0% year-over-year; the trailing twelve-month figure through Dec 2025 was 1250.51% (up 149562.0% YoY), and the FY2025 annual result was 288.26%, down 4313.0% from the prior year.
- EBT Margin advanced to 1021.92% in Q1 2025 per WHWK's latest filing, from 252.42% in the prior quarter.
- Over five years, EBT Margin peaked at 1021.92% in Q1 2025 and troughed at 4563.33% in Q1 2021.
- A 5-year average of 498.59% and a median of 266.35% in 2022 frame the typical range for EBT Margin.
- The sharpest annual moves came in 2021 and 2022: EBT Margin sank 17151 bps in 2021, then soared 396268 bps in 2022.
- A 5-year view of EBT Margin shows it stood at 114.21% in 2021, then tumbled by 133 bps to 266.35% in 2022, then rose by 3 bps to 257.18% in 2023, then advanced by 2 bps to 252.42% in 2024, then surged by 505 bps to 1021.92% in 2025.
- Business Quant data shows WHWK's EBT Margin at 1021.92% in Q1 2025, 252.42% in Q4 2024, and 173.95% in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 6.40% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 41.95% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Whitehawk Therapeutics | 310.18 Mn | 187.14 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 1,021.92% |
| Dec 31, 2024 | -252.42% |
| Sep 30, 2024 | -173.95% |
| Jun 30, 2024 | -235.98% |
| Mar 31, 2024 | -341.64% |
| Dec 31, 2023 | -257.18% |
| Sep 30, 2023 | -273.57% |
| Jun 30, 2023 | -289.76% |
| Mar 31, 2023 | -259.47% |
| Dec 31, 2022 | -266.35% |
| Sep 30, 2022 | -340.97% |
| Jun 30, 2022 | -531.28% |
| Mar 31, 2022 | -600.65% |
| Dec 31, 2021 | -114.21% |
| Mar 31, 2021 | -4,563.33% |
| Dec 31, 2020 | 57.29% |
| Sep 30, 2020 | -1,251.52% |
| Jun 30, 2020 | 61.84% |
| Dec 31, 2018 | -397,322.25% |
| Sep 30, 2018 | 61.26% |